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INTRODUCTION
The immune system responds to injury or irritation through an
innate cascade known as inflammation. There are many cellular
and biochemical events which occur as a result of tissue injury
which are responsible for the outcome of inflammation. Central
to the formation of inflammation are the inflammatory mediators,
which include proteins, peptides, glycoproteins, cytokines, arachi-
donic acid metabolites (prostaglandins and leukotrienes), nitric
oxide, and oxygen free radicals. These compounds are produced
by epithelial cells, endothelial cells, and infiltrating inflammatory
cells. Inflammatory mediators are a double-edged sword, having
the potential to fight off infection, but also to damage the host.
Otitis media (OM) is an inflammatory response to either acute or
persistent stimuli, typified by the accumulation of both cellular
and chemical mediators in the middle ear cleft (1). These media-
tors have a role in the inflammatory processes of the middle ear
such as vascular permeability changes, chemotaxis, stimulation of
epithelial secretory activity, enhancement of mucous glycopro-
tein secretion, and production of other mediators. This paper
aims to review the important studies of inflammatory mediators in
the pathogenesis of OM and cholesteatoma in order to elucidate
which mediators are the most significant. In addition, this paper
reviews studies that have identified possible key factors respon-
sible for the chronicity of OM.
INFLAMMATION AND OM
Initiation of inflammation
OM is frequently caused by bacteria which enter the middle ear
from the nasopharynx via the eustachian tube. In cases of bac-
terial otitis media, the source of bacteria is currently believed to be
the nasopharyngeal tonsils (adenoids). However, cases of sterile
OM are not uncommon and the mechanism of this condition is
This review deals with the characteristics of various inflammatory mediators identified in the middle ear during otitis media
and in cholesteatoma.  The role of each inflammatory mediator in the pathogenesis of otitis media and cholesteatoma has
been discussed. Further, the relation of each inflammatory mediator to the pathophysiology of the middle and inner ear
along with its mechanisms of pathological change has been described. The mechanisms of hearing loss including sensorineur-
al hearing loss (SNHL) as a sequela of otitis media are also discussed. The passage of inflammatory mediators through the
round window membrane into the scala tympani is indicated. In an experimental animal model, an application of cytokines
and lipopolysaccharide (LPS), a bacterial toxin, on the round window membrane induced sensorineural hearing loss as
identified through auditory brainstem response threshold shifts. An increase in permeability of the blood-labyrinth bar-
rier (BLB) was observed following application of these inflammatory mediators and LPS. The leakage of the blood com-
ponents into the lateral wall of the cochlea through an increase in BLB permeability appears to be related to the sensorineur-
al hearing loss by hindering K
+ recycling through the lateral wall disrupting the ion homeostasis of the endolymph. Further
studies on the roles of various inflammatory mediators and bacterial toxins in inducing the sensorineumral hearing loss
in otitis media should be pursued.
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Reviewcurrently unclear. Endotoxin, a component of bacterial cell walls,
is believed to be responsible for initiating inflammation in the mid-
dle ear. Endotoxin is a potent inducer of various inflammatory
mediators, as well as a modulator of the immune response, and
stimulates local macrophages to produce tumor necrosis factor-α
(TNF-α ) and interleukin-1β (IL-1β ). In addition, keratinocytes have
the ability to produce many soluble mediators independently from
immune cells in response to injury, including TNF-α , IL-β , IL-1,
IL-6, and IL-8 (2-5). Many of these cytokines contribute to the acute
phase of the inflammatory response, prime the immune system
for rapid activity, and promote the release of other cytokines
(Fig. 1).
Sources of inflammatory mediators
Inflammatory mediators important in OM are produced by infil-
trating immune cells such as neutrophils, monocytes, and lym-
phocytes. In addition, local cells such as keratinocytes and mast
cells have been shown to produce inflammatory mediators. It is
also coming to light that besides the middle ear, the inner ear tis-
sues are able to produce inflammatory cytokines and use NF-κ B
activation (6). The sources and functions of inflammatory medi-
ators involved in OM are summarized in Table 1.
Complements
Complement is one of the first mediators activated in the initia-
tion of inflammation throughout the body and in OM. This path-
way can act as the first cytotoxic response to invasion while also
initiating recruitment of leukocytes and vascular changes.
Complement is part of the humoral immune system and consists
of multiple components that when activated, usually through cleav-
age, interact to form enzymes or function as binding proteins. In-
travascular activation of complement is initiated via a variety of
agents including antigen-antibody complexes, bacterial products,
and toxins; injured endothelial cells can also activate the comple-
ment system (7). The complement system is organized as two path-
ways with C3 occupying the central position in both. Binding of
antibody to antigen or to foreign molecules results in activation
of the antibody-dependent classical pathway, whereas the alter-
native pathway is activated by the lipopolysaccharide (LPS) por-
tion of endotoxin and other nonprotein agents. C3 is biological-
ly inactive, but cleavage by C3 convertase yields active fragments
including C3a and C3b. Deposition of the active cleavage prod-
uct C3b on the surface of foreign particles or target cells allows
recognition by receptors on phagocytic cells. C3a is a potent activa-
tor of mast cells and basophils and leads to release of histamine
from secretory granules. Proteolytic cleavage of C5 occurs via
both pathways and generates C5a, a potent mediator of inflam-
mation. C5a is the major complement-derived chemotactic agent
for neutrophils, eosinophils, monocytes, and macrophages. C5a
also has the ability to activate platelets, leading to their aggrega-
tion and surface expression of P-selectin.
Complement activation has been observed in human middle
ear effusion by some authors (8, 9). In animal models of acute
otitis media (AOM), animals were treated with cobra venom to
deplete complement and then their middle ears were antigeni-
cally challenged (10). Complement-depleted animals had signif-
icantly less inflammation and decreased volume of effusion when
compared to controls. Middle ear mucosa from children with chron-
ic otitis media (COM) with effusion has shown large amounts of
complement fragments C3 and C9 when analyzed by immuno-
fluorescence microscopy (11). In humans, deficiencies of the com-
plement system are known to cause recurrent or COM (12). Des-
pite this fact, it appears that complement itself may be harmful
to the middle ear mucosa. Membrane cofactor protein (MCP) and
protectin (CD59) are two middle ear proteins which help prevent
unrestricted complement damage (11). 
Cytokines
Cytokines are glycoproteins, produced by inflammatory cells and
epithelial cells, which modulate the immune response. Cytokines
extensively conduct inter-cell communication. Inflammatory cells
including neutrophils, macrophages, and lymphocytes use cytokines
to coordinate all stages of the inflammatory response. Production
of cytokines is conducted by a wide variety of cell types. For exam-
ple, IL-1 is produced and secreted by macrophages, lymphocytes,
vascular endothelial cells, neutrophils, fibroblasts, and monocytes.
There are many biological effects including: chemotaxis of cytotox-
ic T-cells and B-lymphocytes, cytokine synthesis of IL-2 and IL-
8 and TNF, neutrophil chemotaxis and degranulation, fibroblast
and epithelial proliferation, and histamine release (13, 14). The
present theory is that cytokines are responsible for many of the
inflammatory changes induced by pathogenic organisms during
OM (15).
Different cytokines are involved in the early and late stages
of inflammation and it has been observed in a bilateral study of
effusion that cytokine production and concentration can vary
between the ears (16). IL-1 and TNF-α are early-response cytokines
with IL-1 being a more potent activator than TNF-α (17). IL-1 may
be more important than TNF-α in the elicitation stage of inflam-
mation, while there is more of a need for TNF-α during recruit-
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Fig. 1. Pathogenesis of otitis media.
Infection
Sequelae
Mediators
of
inflammation
Eustachian
tube
dysfunction
Mechanical
Functional
Bacterial
Viral
Other Increased
vascular
permeability
Epithelial
secretory
activity
Middle
ear
inflammation
and
effusion
Resolution
ComplicationsJuhn SK et al.: Otitis Media and Inflammatory Mediators 119
Inflammatory mediator Source Principal activities
Table 1. Sources and functions of inflammatory mediators important in otitis media
(Continued to the next page)
Cytokines
Tumor necrosis factor-α Macrophages Prostaglandin release, activates neutrophils, eosinophils, macrophages, cytokine release
Lymphocytes
Epithelial cells
Endothelial cells
Interleukin-1 Macrophages Activates B- and T-cells, epithelial and fibroblast proliferation, cytokine synthesis, 
Neutrophils histamine release, induces fever, bone resorption
Fibroblasts
Endothelial cells
Epithelial cells
Interleukin-2 T-cells Activates T-cells
Interleukin-4 T-cells Stimulates TH2 differentiation and proliferation, anti-inflammatory action on T cells, 
Mast cells B cells, monocytes
Basophils
Interleukin-5 T-cells Stimulates and maintains IgA production by B-cells, eosinophil chemotaxis
Mast cells Stimulates eosinophil production in bone marrow
Basophils
Interleukin-6 Macrophages Activates B- and T-cells, production of antibodies, induces fever, bone resorption
Lymphocytes
Epithelial cells
Interleukin-10 Macrophages Down regulates inflammatory properties of IL-1, IL-6, TNF-α
Interleukin-12 Macrophages Interferon release, activates macrophages, potentiates T-cell proliferation, cytokine production,
Neutrophils and cytotoxicity of lymphocytes.  Induces TH1 lympocyte development
Langerhans cells
Interleukin-13 T-cells Similar to IL-4; molecular bridge linking allergic inflammation cells to the non-immune cells in
contact with them
Transforming growth factor-β Neutrophils Initiation and maturation of inflammatory processes; recruitment, activation, and proliferation 
Macrophages of inflammatory tissues and cells
Granulocyte-macrophage Macrophages Stimulates production of granulocytes (neutrophils, eosinophils, and basophils)
colony-stimulating factor
Chemokines
Interleukin-8 Macrophages Neutrophil chemotaxis and activation, angiogenesis
Fibroblasts
Epithelial cells
Endothelial cells
RANTES Epithelial cells Monocyte and T-cell chemotaxis
MCP-1 Epithelial cells Monocyte and T-cell chemotaxis
Histamine Mast cells Increases vascular permeability, vasodilation, neutrophil and eosinophil chemotaxis
Basophils
Vascular endothelial Thrombocytes Increases vascular permeability, vasodilation, inflammatory cell infiltration
growth factor
Platelet activating factor Monocyte Chemotaxis and degranulation of neutrophils, increase vascular permeability
Neutrophils (1,000×more potent than histamine)
Lymphocytes
Mast cells Bone marrow Release of preformed mediators: histamine and tryptase
expressing CD34 Release of de novo synthesized mediators: leukotrienes and prostaglandins
molecule
Arachidonic acid metabolites
Prostaglandins
Prostaglandin E2 Mast cells Vasodilation, mucus production, induces cytoprotection to IL-1
Neutrophils
Monocytesment and maintenance stages (18, 19). IL-1 and TNF-α from mac-
rophages induce the expression of glycoprotein adhesion mole-
cules on the surface of vascular endothelial cells which bind leuko-
cytes so they can leave the circulation and enter the site of infec-
tion.
IL-1
IL-1 was originally identified as a lymphokine that was mitogenic
for murine thymocytes (20). Now IL-1 is known to be produced
by many different cells to regulate immune responses (21). IL-1
is one of the most active substances inducing bone resorption
through osteoclast activation (22). This IL-1-mediated bone destruc-
tion is one of the clinical characteristics that signal the onset of
chronic OM. Neutrophils are a major producer of IL-1β . IL-1
induces the production of IL-1 in neutrophils in a positive-feed-
back mechanism (23). IL-1 has been shown to stimulate the syn-
thesis of TNF, IL-2, IL-6, and IL-8 (24-27). IL-1 is comprised of
two principal 17kDa polypeptides, IL-1α and IL-1β . Genes found
on chromosome 2 encode these two molecular species (28). They
have the same biological activities and bind to the same recep-
tor on cell surfaces (28, 29). Both IL-1αand IL-1βare derived
by proteolytic cleavage of 33 kDa precursor molecules (28). IL-
1αacts as a membrane-associated substance, whereas IL-1βis
found free in the circulation (30).
IL-1 promotes the release of other cytokines and stimulates
arachidonic acid metabolism in both cyclooxygenase and lipoxy-
genase pathways (21, 31). IL-1 is primarily synthesized by acti-
vated macrophages. In these, IL-1 production is stimulated by
LPS and leukotrienes (28, 32, 33). TNF also stimulates synthe-
sis of IL-1 (14). Platelet activating factor (PAF) can enhance IL-
1 release by the production of leukotriene metabolites (34). IL-
1β is mainly produced and released extracellularly by inflamma-
tory cells such as macrophages/monocytes (35) and IL-1α is local-
ized intracellularly or on the surface of such cells (36). IL-1 induces
cell adhesion molecules (intercellular adhesion molecule-1 and
vascular cell adhesion molecule-1) that in turn stimulate the migra-
tion of leukocytes (18, 37).
IL-lβ has been shown to play an important role in the patho-
genesis of otitis media with effusion (OME). When introduced
into the murine middle ear, endotoxin derived from Haemophilus
influenzae produced middle ear effusion (MEE) with significant-
ly higher levels of IL-1β than controls, and inoculation of IL-1β
caused similar pathologic changes to that of endotoxin. It has been
observed that IL-1β upregulates the activity of sodium-potassium-
chloride cotransporters. Also, IL-1βsuppresses epithelial Na
+
channel-dependent fluid transport. This upregulation of cotrans-
porters may be one of the important factors in the excess fluid
accumulation that is observed in OM (38, 39). 
Additionally, the administration of anti-IL-1 receptor antibod-
ies with endotoxin reduced the incidence of MEE and the patho-
logical changes of the middle ear mucosa (40). Viable pneumo-
cocci inoculated into the middle ear of chinchillas caused an in-
creased concentration of IL-1βafter 6 hr (41). In a guinea pig
OM model induced with nonviable H. influenzae, Sato et al.
(42) suggested that IL-1β and TNF-α were produced by middle
ear mucosa in the early stage of OM, which caused subsequent
inflammatory cell accumulation and further production of
cytokines such as IL-8 and TNF-α in the late stage.
Barzilai et al. (43) showed that IL-1 levels were significantly
higher in culture-positive versus culture-negative AOM. Levels
of IL-1 significantly decreased on days 4-5 of antibiotic therapy
whether the bacteria were eradicated or not. This is in contrast
to measured levels of TNF-α , which are more closely correlated
with the presence of bacteria (44). On the other hand, it has
been shown that age is inversely related to the concentration or
detection rate of IL-1βby enzyme-linked immunosorbent assay
(ELISA) in the MEE of OME patients. Therefore, treatment that
reduces IL-1βmay be an effective adjuvant in the early stage of
OM in children (45, 46).
IL-2
IL-2 is a 15.5 kDa glycoprotein synthesized principally by acti-
vated T cells, although activated B cells may also have the ability
to produce small amounts of IL-2 (47). The gene of IL-2 is locat-
ed on human chromosome 4q26. It induces the proliferation and
differentiation of T-cells, B cells, NK cells, monocytes, and macro-
phages. Upon release, IL-2 is bound by T-cells that have been
primed by exposure to their distinctive antigens. Helper T-cells
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Inflammatory mediator Source Principal activities
Table 1. (Continued from the previous page) Sources and functions of inflammatory mediators important in otitis media
Prostaglandin I2 Endothelial cells Vasodilation, inhibits platelet aggregation
Leukotrienes
LTB4 Neutrophils Chemotaxis and degranulation of neutrophils
LTC4, LTD4, LTE4 Mast cells Increased vascular permeability, vasoconstriction
Basophils
Eosinophils
Bradykinins Plasma Increased vascular permeability, pain
RANTES: regulated upon activation, normal T-cell expressed and secreted; MCP-1: monocyte chemotactic protein-1; IL-1: interleukin-1; TNF-α : tumor necro-
sis factor-α .stimulated by IL-2 secrete cytokines to stimulate other lympho-
cytes. Cytotoxic T-cells and natural killer cells stimulated by IL-
2 also proliferate and secrete cytokines, IFN-γ , granulocyte-
macrophage colony-stimulating factor (GM-CSF), and TNF-α
which preferentially activate monocytes and macrophages. IL-2
reaches peak levels early in the inflammatory cascade, and lev-
els quickly drop before there is any clinical evidence of inflamma-
tion. IL-2 is a key factor in determining the TH1 response of T-
cells to promote a strong cell-mediated response. TH1 cells are
responsible for orchestrating cellular immunity, while TH2 cells
(stimulated by IL-4) provide signaling for humoral immunity.
However, IL-2 was not detected in MEE of AOM patients by
ELISA nor was it found in an experimental rat model of AOM
induced by inoculation of Streptococcus pneumoniae type 3 and
nontypable H. influenzae by reverse transcription-polymerase
chain reaction (RT-PCR) (44, 48). On the contrary, IL-2 was detect-
ed in the MEE of the chronic OME patients by ELISA (45, 49).
It is believed that the inflammatory up-regulation of IL-2 is bal-
anced by the down-regulatory effects of IL-10. Smirnova et al.
(50) reported that an imbalance in the production of these cytokines
induces switching to the chronic stage. Excessive IL-2 produc-
tion can cause humoral inflammatory processes and/or chronic
cell-mediated processes whereas IL-2 deficiency promotes per-
sistence of OME, which can result in chronic OME. From this, it
may be deduced that the ongoing chronic inflammatory state
associated with chronic OME may contribute different cell types,
and thus different cytokines, than those with AOM.
Tumor necrosis factor (TNF)
TNF is a pair of cytokines originally called cachectin (TNF-α ) and
lymphotoxin (TNF-β ). TNF-α is a polypeptide produced mainly
by stimulated macrophages but made by wide variety of cells
including fibroblasts, T cells and B cells (51). TNF-β is produced
predominantly by lymphocytes and its active form is a 25 kDa
glycosylated polypeptide (52). These two forms of TNF are 30%
identical at the amino acid level (53).
Endothelial cells and epithelial cells all have the capacity to pro-
duce TNF. TNF induces the acute phase of the inflammatory res-
ponse and release of other cytokines. TNF activates polymor-
phonuclear leukocytes, promotes fibroblast proliferation, inhibits
vascular endothelial and B-lymphocyte proliferation, and stim-
ulates cartilage and bone resorption (54). Thus, TNF has many
of the same functions as IL-1. In fact, IL-1β and TNF-α induce each
other’s production and have a synergistic effect in vivo (55-57).
TNF stimulates arachidonic acid metabolism, leading to the pro-
duction of prostaglandins and leukotrienes that are important in
the pathogenesis of OM (58, 59). TNF-αis a strong inducer of
IL-1, IL-2, IL-6, IL-8, and endothelial adhesion molecules includ-
ing intercellular adhesion molecule-1 (ICAM-1) and vascular cell
adhesion molecule-1 (VCAM-1) (60-63). TNF-αis chemotactic
to neutrophils, monocytes, macrophages, and lymphocytes (17).
TNF-α was detected in human MEE and it is now apparent that
TNF-α is one of the most significant inflammatory mediators in
OM (64). Animal models of OM induced by S. pneumoniae and
LPS have all demonstrated elevated levels of TNF-α in the early
stage of OM. Ball et al. (65) indicated that TNF is a significant
mediator of LPS-induced MEE in a rat model. Higher expression
of TNF-αin human OM confers higher risks of subsequent
episodes of OM, longer courses of OM, and chronicity of OM (66-
68). The results of these studies suggest a potential therapeutic
role with the clinical application of TNF inhibitors, such as TNF
binding protein or inhibitor TNF soluble receptor, to control the
symptoms of AOM or to prevent chronicity and recurrence of
OM (65, 66). 
IL-4, IL-5, IL-13, and GM-CSF
IL-4, a 20 kDa glycosylated polypeptide, is produced mainly by
CD4+ T cells, but also by mast cells and basophils. It functions
primarily as a growth factor for B cells and some types of T cells
(14). IL-4 supports the proliferation of activated T cells and dri-
ves their differentiation to TH2 cells. These T cells support the
production of antibodies in a humoral immune response. IL-4
stimulates B-cells to increase IgG and IgE isotypes (21). There
are also anti-inflammatory effects that are stimulated by IL-4. It
controls numerous molecular processes which cause deactivation
of inflammatory macrophages, suppression of inflammation, down-
regulation of the production and secretion of pro-inflammatory
cytokines TNF-α , IL-1, and IL-8 (50). Although Melhus et al. (48)
reported that they could not detect mRNA of IL-4 in the animal
AOM model induced by S. pneumoniae and H. influenzae, Jang
and Kim (49) could detect IL-4 in the MEE of chronic OME patients
and suggested that elevation of TH2 cytokines, such as IL-4 and
IL-6, might be a contributing factor in the persistence of OME
with allergy. In addition, IgG production shows increases in rela-
tion to IL-4 prevalence in AOM in systemically immunized mice
due to IL-4 having the effect of inducing B-cell differentiation into
IgG-secreting plasma cells (69). It is thought that this is the path-
way leading to inflammation in patients with allergic disorders
causing OM. Smirnova et al. (50) reported that switching from
acute to chronic inflammation can be induced by IL-4 due to its
ability to up-regulate mannose receptor expression on activated
macrophages. Activated macrophage fusion and giant multinu-
cleate cell formation are promoted by the mannose receptor and
create the cellular background for the onset of chronic inflam-
mation.
IL-5 is produced by T lymphocytes as a glycoprotein with a
Mr of 40-45 and is also involved in the TH2 pathway of inflam-
mation (70). IL-5 functions to induce differentiation of eosinophils
and augments proliferation of activated B-cells (14). IL-5 specif-
ically acts on B-cells to stimulate and maintain IgA production
(71). In chronic otitis media with effusion (COME) in systemi-
cally immunized mice, IL-5 positive cells were more numerous
than IL-4 cells (69). This finding is consistent with the finding of
increased local IgA production seen during chronic otitis media
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Recent findings by Iino et al. suggest that IL-5 may play a key
role in the pathogenesis of eosinophilic otitis media (EOM), a form
of infection often associated with bronchial asthma and/or aller-
gic rhinitis. EOM is commonly seen in adults in contrast to AOM
and OME which are more often diagnosed in children. The role
of IL-5 in EOM can be linked to its chemotactic effect on eosino-
phils. EOM is characterized by having a markedly viscous or gelati-
nous effusion with a high eosinophil count and middle ear mucous
membranes that are thickened with numerous eosinophils. The
eosinophilic infiltration is thought to be due to locally produced
IL-5. Iino et al. (72) showed that higher concentrations of IL-5
appeared in EOM middle ear effusions than in those of OME
patients. This finding is further evidence of the role IL-5 has in
EOM and OME patients.
IL-13 has also been implicated in the pathogenesis of OME. This
inflammatory cytokine was found in 25.9% (7/27) of effusions
in a study by Smirnova et al. (73) It was also found that both IL-4
and IL-13 had a significant positive correlation with the concen-
tration of mucin in MEEs. It has been shown in an allergic air-
way inflammation model that suppress both IL-4 and IL-13
may be necessary to reduce mucus production and allergic
inflammation (74). More research is needed to understand the
functions of how IL-13 works in conjunction with IL-4 as a pro-
inflammatory cytokine during OM.
GM-CSF has also been found to play a role in OM. GM-CSF
promotes the activation and prolonged existence of eosinophils.
Together with IL-5, it is possible that up-regulation of GM-CSF
can cause eosinophil-mediated inflammation. In contrast, GM-CSF
may also prove to be a down-regulator of allergic inflammation
due to its ability to induce apoptosis in eosinophils (75). Further
research is necessary to gain a better understanding of GM-CSF
in the middle ear.
IL-6
IL-6 is a glycoprotein with a molecular weight of 25 kDa. IL-6 is
produced by many cells, including helper T-cells, macrophages,
mast cells, neutrophils, epithelial cells, and fibroblasts. It stimu-
lates B cells to differentiate and is often upregulated following
infection (76). Its main function is regulation of immune response,
acute phase reaction, and hematopoiesis (77). IL-6 has been shown
to play a key role in the acute phase reaction, including the induc-
tion of C-reactive protein (78). C-reactive protein is commonly
used as a marker of bacterial infection. However, its use as a screen-
ing test for bacterial AOM is limited by its limited sensitivity and
negative predictive value (79).
IL-6 seems to play an important role in the cytokine network
of OM. The concentrations of IL-1, IL-6, and TNF-α in MEE from
children were highly correlated with each other (80). Kerschner
et al. (81) also discovered a significant correlation between MEE
IL-6 concentrations and degree of hearing loss. In cultured mid-
dle ear epithelial cells, mucin secretion is upregulated by IL-6 in
a dose and time-dependent manner. Interestingly, in a study of
children with AOM, serum samples from the AOM patients infect-
ed with S. pneumoniae contained significantly higher levels of
IL-6 than those infected with other bacteria or no bacteria (82).
It appears that S. pneumoniae stimulates IL-6 production more
than other types of bacteria. On the contrary, IL-6 was not detect-
ed in the guinea pig OM model induced by nonviable H. influen-
zae (41). Fogle-Ansson et al. (83) found that animals inoculated
with gram-negative bacteria mediated a faster IL-6 response than
animals inoculated with gram-positive bacteria. They also found
that it was possible to determine whether an infection was gram-
positive or negative by analyzing the concentrations of IL-6. In
a rat model, IL-6 mRNA increased in AOM induced by both S.
pneumoniae and H. influenzae (48). Additionally, it was found
that the shorter the course of OM, the higher the concentration
of IL-6 in MEE (67).
In conclusion, expression of IL-6 is thought to be a potential can-
didate for the detection of the severity or chronicity of AOM. Fu-
rther proof of this can be seen in the recent findings linking IL-6
to mucin upregulation. However, more reports demonstrating
direct correlation between IL-6 and upregulation of mucin secre-
tion are necessary to show transition to chronicity of OM. 
IL-10
IL-10, known as cytokine synthesis inhibitory factor, is consid-
ered an immunosuppressive regulator of acute inflammation. It
is produced by monocytes, CD4+ T cells, activated CD8+ T cells,
and activated B cells following induction by bacterial products
such as LPS. It is produced relatively late when compared to other
cytokines, but there is evidence that IL-10 expression is upreg-
ulated shortly after or even simultaneously with pro-inflammatory
cytokines. IL-10 is the principal TH2-type cytokine that upregu-
lates humoral immune responses and attenuates cell-mediated
immune reactions. If IL-10 is present for an extended period in
the inflammation zone it can induce the amplification of chron-
ic humoral inflammatory processes. Through this humoral inflam-
matory amplication IL-10 is thought to contribute to the switch-
ing of the infection into the chronic stage. A deficiency of IL-10
has also been seen to result in the chronic condition because the
inflammatory actions of IL-1β , TNF-α , and IL-6 are not downreg-
ulated (50). IL-10, being the key anti-inflammatory cytokine,
inhibits monocytes/macrophages and the production of TNF,
IL-1, IL-6 and IL-8 (84). In addition, the production of oxygen
radicals and proteases from activated neutrophils is directly sup-
pressed. IL-10 was detected in the MEE of an experimental OM
model by ELISA (85), and middle ear mucosal upregulation of
its mRNA expression was also reported in the early and in the
late stage of experimentally induced OM (48, 85). It is thought
that IL-10 contributes to the eradication of middle ear inflam-
mation and provides a negative feedback mechanism related to
TNF-αin OM.
It is also believed that production of IL-10 must be balanced
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′relative to production of IL-2. These cytokines need to be pro-
portional in the middle ear in order to cancel the effects of the
other. IL-10 is responsible for the down-regulation of acute inflam-
matory events while IL-2 leads to the up-regulation of cellular
and molecular inflammation events (50).
Transforming growth factor (TGF)
TGF is divided into two classes of polypeptide growth factors.
Transforming growth factor alpha (TGF-α ) and beta (TGF-β )
are not structurally or genetically related to one another and
they act through different receptor mechanisms. TGF-β is known
to exist in at least five subtypes: TGF-β 1 through TGF-β 5. TGF-β
is part of a supergene family of low molecular weight cytokines
that play a crucial role in the initiation and maturation of inflam-
matory processes including recruitment, activation, and prolifer-
ation of inflammatory cells (86). TGF-β has been found to stimu-
late extracellular matrix formation (fibronectin, collagen, and
proteoglycans), protease inhibitor, and fibroblast chemotaxis.
TGF-β is also believed to have an effect on fibroblast prolifera-
tion (87). The overproduction of TGF-βin the middle ear can
elicit responses that may lead to chronic OME. Fibroblast accu-
mulation and activation, IgA+ B cell secretion, and monocyte accu-
mulation and activation are the result of TGF-βoverproduc-
tion. In the presence of cytokines such as IL-10, IL-4, and GM-
CSF, these effects can cause cell-mediated inflammation, humoral
inflammation, and progressive fibrosis which leads to the chron-
ic condition of OME (50). In a study by Cooter et al. (86), it was
found that detectable amounts of TGF-β 1 and TGF-β 2 occurred in
100% and 98% of middle ear effusions, respectively. The major
role of TGF-β occurs in the later stages of inflammation and its
higher levels indicate that it participates in the repair of dam-
aged tissue in the middle ear (50).
IL-12
IL-12, a heterodimeric pro-inflammatory cytokine, is produced
by phagocytic cells such as macrophages, neutrophils, and Langer-
hans cells. When stimulated by bacteria or bacterial toxins such
as LPS, these cells release large amounts of IL-12. This effect is
further enhanced in the presence of interferon-γ (IFN-γ ). IL-12 is
a potent inducer of IFN-γ production by T and NK cells. IL-12-
induced IFN-γ exerts positive feedback in inflammation by enhanc-
ing IL-12 production. Wang et al. (88) found that IL-2 upregu-
lates the expression of IL-12 and increases the response of NK
to IL-12. IL-12 is the major cytokine responsible for the differ-
entiation of TH1 cells, which are producers of IFN-γ . The enhanc-
ing effect of IFN-γ on IL-12 production may represent a mecha-
nism by which TH1 responses are maintained. IFN-γactivates
macrophages and NK cells, and potentiates the proliferation of
activated T cells. IL-12 is important in early immunity because
it stimulates innate resistance and generates a TH1-type immune
response. It is believed to form a link between innate and adap-
tive immunity. There have been no reports about the expres-
sion of IL-12 in OM until now. It is thought that the function of
IL-12 in the middle ear is limited.
Chemokines
Chemokines are a family of structurally similar small proteins,
whose major role is to stimulate leukocyte chemotaxis (89). In
this way, they are thought to regulate the immune response. There
are 2 families of chemokines, α -chemokine (CXC) and β -chemo-
kine (CC) chemokines. CXC chemokines include IL-8 and are
chemotactic to neutrophils. CC chemokines are chemotactic to
monocytes and lymphocytes.
IL-8
IL-8 comes from monocytes, macrophages, fibroblasts, endothe-
lial cells, and lymphocytes (90). It is produced on stimulation with
IL-1β , TNF-α , IL-13, LPS, Concanavalin A, or viruses from the
previously listed cells (5, 17, 91, 92). Since IL-8 expression can
be controlled by the primary cytokines, IL-1βand TNF-α , it is
considered to be a secondary cytokine in middle ear inflammation
(73). IL-8 is a selective chemotaxic agent for neutrophils (93, 94).
IL-8 induces neutrophil chemotaxis, activation and degranulation,
surface expression of adhesion molecules, respiratory burst, and
cytosolic calcium increase (93). IL-8 increases adhesion molecules
for attachment and migration of neutrophils during acute inflam-
matory response (95). Since IL-8 is capable of inducing lysoso-
mal enzyme release, IL-8 may play a key role in causing tissue
damage, which leads to the prolongation of middle ear inflam-
mation (96, 97). When directly injected into the middle ears of
healthy mice, IL-8 causes more inflammatory changes than when
S. pneumoniae is injected into mouse middle ears (98). IL-8 secre-
tion is enhanced in both S. pneumoniae and H. influenzae pro-
voked cases of OM (73).
Several authors detected IL-8 in human MEE. Transcripts of
IL-8 were detected in 75% of both pediatric and adults MEEs (97).
The mean level of IL-8 in MEE from children was higher than
that of adults (99). The peak level of TNF-α and IL-1β in the MEE
in a guinea pig OM model preceded the peak in IL-8 (41). This
delay of the IL-8 peak level suggests that IL-8 is produced by inf-
lammatory cells which accumulated via the influence of TNF-α
and IL-1β .
Levels of IL-8 were closely correlated with the presence of bac-
teria and neutrophils in the MEE of OM. With initiation of antibi-
otic therapy, levels of IL-8 were reported to fall as bacteria were
eradicated from the middle ear (100). IL-8 has also been shown
to be predictive of the number of neutrophils in MEE (100-103).
Smirnova et al. (104) assessed the effects of IL-8 and other proin-
flammatory cyokines on goblet cells using human goblet cell line
HT29- MTX which secretes two OME-related mucins, MUC5AC
and MUC5B. They proposed that goblet cells are target cells for
IL-8, TNF-α , and IL-1β and that IL-8 stimulates prolonged mucin
secretion from goblet cells and may be involved in the mainte-
nance of OM in the the chronic stage. Additionally, recurrence
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the initial middle ear fluid (101). The results of these studies sug-
gest the possibility of using the IL-8 level as a prognostic factor or
parameter of clinical outcomes. 
Monocyte chemotactic protein-1 (MCP-1)
MCP-1 is expressed by endothelial cells, fibroblasts, and epithelial
cells stimulated by either IL-1 or TNF (18). MCP-1 is chemotac-
tic for both monocytes and lymphocytes in vitro (105, 106).
Recently, MCP-1 has been shown to be chemotactic for mono-
cytes and lymphocytes in vivo (107). MCP-1 expression alone
does not activate these cells, but leads to enhanced inflammato-
ry response upon treatment with other stimuli such as LPS
(107). MCP-1 increases the adhesiveness of human monocytes
toward endothelial cells by stimulating an increase in the surface
expression and activation of adhesion molecules (108, 109).
MCP-1 has a central position in monocyte trafficking and activa-
tion and has been implicated in diseases characterized by
monocyte-rich infiltrates, including atherosclerosis, rheumatoid
arthritis, and multiple sclerosis (110). MCP-1 is important in
recruiting monocytes in chronic inflammation (17). MCP-1 has
been detected in higher levels in MEEs with combined bacterial
and viral infections (111). MCP-1 can be seen to upregulate the
activation of inflammatory cells in the presence of LPS. 
Macrophage inflammatory protein-1 (MIP-1 )
MIP-lαis released by monocytes, mast cells, endothelial cells,
fibroblasts, epithelial cells, B cells, and T cells. It has potent mono-
cyte and lymphocyte chemoattractant properties and induces
release of histamine from basophils and mast cells (112, 113).
MIP-1α was detected 9 of 11 cases of MEE (111). It is likely that
MIP-1 plays an important role in the microenvironment of the
middle ear, especially with respect to basophil function (111). This
mediator has the potential to be important in acute and chronic
OM as it is released by monocytes and induces histamine release
and monocyte chemotaxis. 
RANTES
Regulated upon Activation, Normal T-cell Expressed and Secreted
(RANTES) is a CC chemokine that is chemotactic to monocytes
and lymphocytes. RANTES was reported to be detectable in 94
(82%) of 114 effusions. The concentration of RANTES was pos-
itively correlated with the endotoxin content (114). In vitro,
RANTES was expressed in middle ear epithelium in response to
proinflammatory stimuli (TNF-α ) in a dose dependent manner.
Schousboe et al. (114) speculated that the expression of RANTES
might explain the recruitment of monocytes in OME, possibly as a
result of TNF-α -mediated endotoxin stimulation. On the other
hand, Jang and Kim (115) demonstrated that RANTES and
eosinophilic cationic protein (ECP) in MEE of OME with allergy
were significantly correlated and significantly higher than con-
trols. Their results suggest the allergic role of chemokines in the
pathogenesis of OME. 
Mast cells
Mast cells are the most numerous resident leukocytes in the mid-
dle ear. When activated, mast cells release preformed mediators,
histamine and tryptase, and de novo synthesized mediators, leu-
kotrienes and prostaglandins. Mast cells also release various cyto-
kines including tumor necrosis factor and IL-1. During OM the
mast cell population increases dramatically and mast cells will use
Toll-like receptors and CD48 to directly interact with bacterial
products. Ebmeyer et al. (116) showed that mast cells may be a
major contributor to the early inflammatory response and may
provide a link between infection and allergy in the generation
of OM.
Histamine
Histamine causes vasodilation, increased vascular permeability,
and edema of middle ear mucosa (117-119). Histamine is released
by mast cells present in the middle ear upon activation by either
complement or binding of antigen to IgE antibodies which stud
the exterior surface of mast cells (120-122). Through its vasodila-
tory effects, histamine can cause mucociliary and eustachian tube
dysfunction (123-126). Histamine levels and mast cell numbers
were higher in adenoids of children with serous OM than in chil-
dren with normal ears, suggesting a possible mechanism of eustachi-
an tube obstruction secondary to histamine released from the ade-
noids (127, 128). In addition, middle ear mast cells were increased
twofold in patients with chronic middle ear disease (129). Histamine
levels were found to be higher in mucoid effusions than serous-
type effusions (121, 129). Thus, histamine appears to be an impor-
tant mediator influencing both acute and chronic OME.
Vascular endothelial growth factor (VEGF)
Another factor thought to be responsible for increased vascular
permeability is VEGF. It is extremely potent, estimated to be
50,000 times as potent as histamine (130). Platelet-activating fac-
tor is 1,000-fold more potent than histamine, which may mean
that the permeability effect of VEGF is approximately 50 times
greater than PAF. Kim et al. (131) found that severe inflamma-
tory cellular infiltration, subepithelial edema, and vascular dilata-
tion occurred in Sprague Dawley rats that were exposed to 0.1
μ g and 1.0 μ g of recombinant vascular endothelial growth fac-
tor. It is thought that perhaps VEGF is primarily responsible for
increased vascular permeability and that it is expressed in the
presence of histamine (132).
Bradykinin/kallikrein-kinin system
The plasma kinin-forming system consists of three plasma proteins
that interact in a complex manner when bound to negatively ch-
arged surfaces. These factors are factor XII (Hageman factor), pre-
kallikrein and high molecular weight kininogen (HMWK). Factor
XII, once converted to factor XIIa, converts plasma prekallikrein
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bradykinin. In serous OME, bradykinin enhances the vascular per-
meability in the middle ear mucosa, causing plasma to leak into
the middle ear cleft (133). This plasma leakage characterizes serous
effusions (134). Active plasma leakage into the middle ear occurs
during the early phase of inflammation (133). The degree of plas-
ma leakage is low in mucoid effusions and varied in serous effu-
sions (133). Decreased plasma leakage into the middle ear in mu-
coid effusions may be explained by the consumption of the kalli-
krein system (134). Thus, bradykinin is an acute phase mediator,
induced by the kallikrein-kinin system, which enhances vascular
permeability in the middle ear leading to MEEs.
Platelet Activating Factor (PAF)
PAF is a membrane phospholipid metabolite released through the
remodeling pathway upon stimulation (135). PAF, IL-1, and TNF
can induce each other’s release and also their own generation in
self-generating positive feedback cycles (35). PAF is released from
human neutrophils, platelets, eosinophils, macrophages, mast cells,
and vascular endothelial cells. PAF synthesis is stimulated by PAF,
LTB4, LTC4, and LTD4 (136, 137). Its activities include stimula-
tion of arachidonic acid release and metabolism, increasing vas-
cular permeability, and activation of neutrophils, monocytes, and
macrophages (138, 139). PAF induces neutrophil adhesion to
endothelial cells (137). In addition, PAF appears to play a major
role in the production of MEE by increasing vascular permeabili-
ty, stimulating epithelial secretory activity, and reducing the mu-
cociliary activity of the middle ear causing eustachian tube dys-
function (140). By stimulating mucous glycoprotein release, PAF
appears to be a mediator in the hypersecretion of mucus in the
middle ear cavity and eustachian tube (141). PAF has been shown
to impair mucociliary clearance function in a dose dependent man-
ner (142). The disruption of the mucociliary clearance function
may be partly responsible for chronic MEE. Levels of PAF in sam-
ples of human MEE have been reported to be in the range of
5.5 μ g/mL in purulent otitis media, 7.6 μ g/mL in mucoid otitis
media, and 31.5 μ g/mL in serous otitis media (143). 
Arachidonic acid metabolites: prostaglandins and
leukotrienes
Products derived from the metabolism of arachidonic acid (AA),
also called eicosanoids, affect a variety of biologic processes, includ-
ing inflammation and platelet function (Table 2). AA is derived
from cell membrane phospholipids of certain cells in response to
some stimulus which activates phospholipase A2 (PLA2). Possible
stimuli are many and include antigen-antibody complexes, oxy-
gen free radicals, bradykinin, and thrombin. Leukotrienes (LTs)
and prostaglandins (PGs) are enzymatically formed from AA by
lipoxygenase and cyclooxygenase respectively. Metabolites of
AA have been identified in human MEE as well as in experimental-
ly induced MEE in animals (58, 143, 144). Indomethacin or ibupro-
fen, an inhibitor of prostaglandin-forming cyclooxygenase, has
been reported to be effective in reducing the accumulation of
MEE or mucosal thickness in the animal OM model (145, 146).
However, LTs seem to be more pro-inflammatory than PGs in
otitis media, according to previous animal studies (58, 144). 
AA metabolites can affect the production of cytokines, and cyto-
kines can regulate the production of AA metabolites. PLA2 acti-
vating protein stimulates PLA2 enzymes to break down arachidon-
ic acid. The synthesis of PLA2 activating protein is induced in endo-
thelial cells by IL-1, TNF, LTD4, and bradykinin (147, 148). Ch-
allenging the middle ear-eustachian tube (ME-ET) system with
eicosanoids PGE1 and PGE2 resulted in increases in permeabili-
ty and a vasodilation-edema. LTC4, LTD4, and PGE2 resulted in
decreased ET patency and LTC4 slowed ME-ET clearance, sug-
gesting that LT induces OME partly by impairing mucociliary
transport of eustachian tube mucosa (117, 124, 149).
LTB4 is primarily synthesized by granulocytes and is chemo-
tactic for neutrophils, monocytes, and lymphocytes (150). A
study of experimental pneumococcal OM in chinchillas has sug-
gested that arachidonic acid products, including LTs, in the mid-
dle ear are derived from inflammatory cells, since these products
appeared after influx of inflammatory cells into the area (59). In
animal models of OM, concentrations of LTB4, as well as other
LTs, have been shown to correlate well with the degree of inflam-
mation in the middle ear (146). LTB4 is higher in acute OM than
chronic OM, suggesting it is related to the acute stage of middle
ear disease (101). LTC4 was reported to be the most persistent
eicosanoid in the infected chinchilla middle ear (151). Tada et al.
(152) demonstrated that LTD4 can induce OME by a single inoc-
ulation and OME could last over 14 days, as LTD4 stimulated the
release of proinflammatory cytokines. They also reported that
oral administration of a specific LT antagonist, pranlukast, alle-
viated the experimental OME (152). Other LT-inhibitors, such as
montelukast sodium and SCH/37224, have been shown to have
some efficacy in prevention or treatment of OME experimentally
or clinically (141, 153).
Free radical production in OM
Nitric oxide (NO) is a free radical generated by NO synthase in
many cells and tissues including neurons, macrophages, neutrophils,
endothelial cells, smooth muscle cells, lungs, and respiratory tract
epithelial cells, including middle ear epithelial cells (154). In
OM, it is largely responsible for vasodilation, increased vascular
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Action Metabolite
Table 2. Inflammatory actions of eicosanoids
Vasoconstriction TXA2, Leukotrienes C4, D4, E4
Vasodilation PGI2, PGE1, PGE2, PGD2
Increased vascular permeability Leukotrienes C4, D4, E4
Chemotaxis Leukotriene B4, HETE
HETE: 12-hydroxy 5,8,10,14-eicosatetraenoic acid.permeability, and production of mucoid effusions (155). NO syn-
thesized by activated inflammatory cells regulates the functions
of the other cells involved in the inflammatory process. Thus, NO
may be considered a secondary mediator of inflammation produced
by the middle ear epithelium in response to primary proinflam-
matory cytokines, such as IL-1β and TNF-α (156). Watanabe et
al. (157) demonstrated that both in vivo and in vitro application
of these cytokines resulted in increased iNOS in the middle ear
epithelial cells of rats. Studies have demonstrated that inhibition
of intracellular NO production blocks the hypersecretion of mucin
in guinea pig tracheal epithelial cells stimulated by reactive oxygen
species, TNF-α , PAF, and histamine (158-160). In rat middle ears
injected with lipopolysaccharide, inhibition of intracellular NO
release blocked mucin release (155). NO is also a likely media-
tor of osteoclastic resorption in COM (161). Recent work by Jeon
et al. (162) suggests that NO may be a crucial signaling molecule
that plays a role in nearly every step of OM pathophysiology. It
is also suggested that the damaging effects of NO might be a result
of its metabolite reactive nitrogen species which are products of
the NO and reactive oxygen species reaction. In addition to NO,
various other oxygen free radicals can directly damage middle
ear epithelium. Both S. pneumoniae and neutrophils are known
to produce highly reactive oxygen free radicals which have been
shown to directly damage middle ear mucosa in OM (163).
Acute and chronic inflammatory mediators
IL-1 and TNF-α are early-response cytokines, although IL-1 appears
to be a more potent activator than TNF (17). IL-1β concentrations
were higher in purulent middle ear fluids than in serous or mucoid
MEE (1, 164), and significantly higher concentrations were also
found in patients with culture-positive than in those with culture-
negative AOM (1, 43, 164). On the other hand, high concentra-
tions of TNF-α in MEE were reported to be associated with a his-
tory of multiple placements of tympanostomy tubes (80). Cultured
monocytes, which had differentiated to macrophages, had a mar-
kedly reduced LPS inducible IL-1, but not TNF-α secretion, sug-
gesting that TNF-α may be involved in chronic otitis with differ-
entiated macrophages and bacterial endotoxin retained in the
middle ear cleft (165). MEE from ears with chronic OME have
been assayed for endotoxin and TNF-α with 40% of ears hav-
ing retained endotoxin. There was also a statistically significant
correlation between both TNF-α and IL-1β with endotoxin lev-
els (166). More recently, Hebda et al. (85) demonstrated that
mucosal mRNAs for IL-6, IL-10, IFN-γ , TNF-α , MCP-1, and TGF-β
were upregulated through the 16 weeks of follow-up in an exper-
imentally induced OM. Taken together, endotoxin and upregu-
lated TNF-α production are considered to be important factors
for the persistence or chronicity of OME.
LTB4 and IL-8 are produced during acute infection of the middle
ear and these PMN-related inflammatory substances may play
an important role in delaying recovery or in recurrence of AOM
(101). LTB4, LTC4, PGE2, and PAF appear to be important in the
acute inflammatory process of OM (58, 144, 167). Further research
is needed to gain a better understanding of the roles leukotrienes,
prostaglandins, and platelet-activating factor play on each other
and on the middle ear. 
Inflammatory cells in acute and chronic OM
Neutrophils, monocytes, and macrophages are the major cell types
observed in middle ear effusions (168, 169). Neutrophils are the
predominant cells involved in early host response against OM
during invasion of bacterial pathogens. Neutrophils have been
shown to be associated with the pathogenesis of not only acute
OM but also chronic OME in children (170). Lysozyme accumula-
tion in MEE preceded significant inflammatory cell influx with
lysozyme present at 6 hr and inflammatory cells present after 12
hr in MEE in H. influenzae-induced experimental OM (171). The
predominant cell populations in the mucosa and MEEs in COME
are mononuclear cells, macrophages, and lymphocytes, with plas-
ma and mast cells also present (172-176). Lysozyme is a product
of both PMNs and mononuclear inflammatory cells, with levels
higher in purulent otitis media (POM) than in serous OM (177).
Inflammatory cells recruited to the ME were able to set up a
delayed inflammatory reaction in chronic OM (138). 
In chronic otitis media with repeated episodes of acute inflam-
mation, neutrophils and macrophages infiltrate with each episode
(178). The number of macrophages continued to increase for up
to four weeks after eustachian tube obstruction in chinchillas (177).
As the inflammatory process enters the chronic phase of OM,
there is a continuing shift in the population of infiltrating leuko-
cytes toward increasing numbers of mononuclear cells.
Pediatric and adult otitis media
Most of the human studies discussed focus on children because
adult OM occurs relatively infrequently. There are differences
in the inflammatory mediators involved in child and adult OME.
Higher levels of lysozyme, a nonspecific defense lysosomal enzyme
against bacterial infection, were found in the effusions of children
compared to adults (179). The early response cytokines IL-1β and
TNF-α were present in higher percentages of effusions from chil-
dren than adults (85% of children vs. 12% of adults for IL-1β and
85% of children vs. 8% of adults for TNF-α ), suggesting that adult
OM is associated with lower expression of the early response cy-
tokines (46). These observed differences in OM between children
and adults may be due to adults having more developed immu-
nity to different pathogens.
Histopathology of acute and chronic OM
Acute inflammatory changes include vascular dilatation, sub-
mucosal edema, and infiltration of phagocytic cells into the mid-
dle ear. After the tissue damage has subsided, submucosal fibro-
sis, calcification, ossification, and hypertrophy of squamous epithe-
lia of the tympanic membrane develops (178). Serous otitis media
induced by eustachian tube obstruction in an animal model
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sia of epithelium and edema of the subepithelial space resulting
from increased vascular permeabiltiy. POM induced by inocu-
lation of pneumococci into the middle ear showed histopatho-
logical changes characterized by metaplasia of the epithelial lin-
ing and goblet cells, widening of the subepithelial space with cap-
illary dilatation and neutrophilic infiltration, and the appearance
of lymphocytes and plasma cells (180).
Middle ear mucosal changes in patients with persistent OME
show thickening of the pseudostratified epithelium with an increase
in goblet cell density and pronounced basal cell hyperplasia (181).
Goblet cell proliferation is commonly seen after toxic influence
on respiratory epithelium (182). Under abnormal conditions, the
flat nonciliated epithelium of the middle ear was transformed into
pseudostratified ciliary epithelium with an increase in goblet cells
(183). A study of 123 temporal bones with chronic OM showed
fibrous thickening of the mucoperiosteum and granulation tissue
principally, but subepithelial glandular formation was also a com-
mon finding (184). Influenza virus inoculated into the nose caus-
es an increase in the frequency of goblet cells in the nasopharyn-
geal portion of the eustachian tube (185). Increased frequency
of goblet cells was also induced by pneumococcal antigens in the
bulla of guinea pigs (186). It has also been observed that the ratio
of albumin to immunoglobulin can shed light on the stage of infec-
tion and further deduce the pathomechanics of infection (187).
Many of these changes are caused, in part, by inflammatory medi-
ators in the middle ear.
Bacterial endotoxin and LPS
A percentage of chronic OME may be related to retained bacte-
rial antigens which produce chronic local stimulation of the immune
system contributing to persistence of ME inflammation and effu-
sion (188). Endotoxin is an integral component of the outer mem-
brane of all gram-negative bacteria and consists of a complex of
LPS and protein. The LPS is composed of a lipid portion (lipid A)
linked by 3-deoxy-D-manno-octulosonic acid (KDO) to a heteroge-
nous sugar polymer referred to as O-antigens (189). The gram-
negative OM pathogens, nontypable H. influenzae (NTHi) and
Moraxella catarrhalis, however, do not have O-specific polysac-
charide antigens. Endotoxin from these bacteria is therefore re-
ferred to as being composed of lipooligosaccharide (LOS) and
protein (190).
Middle ear effusions containing 100 ng/mL to 1 μ g/mL of
LPS and 25 to 100 ng/mL of LPS stimulated TNF-αproduction
by cultured human monocytes (191). Therefore, monocytes
and macrophages might be expected to be activated to produce
inflammatory cytokines such as TNF-α , resulting in a chronic
inflammatory response (192). LPS has been shown to induce
production of IL-lβ , IL-6, and TNF-αand significant levels of
IL-1β , IL-6, and TNF-αhave been found in MEEs (45, 193, 194).
LPS is a potent stimulus for the production of macrophage-derived
TNF and IL-1 (195). Non-typeable H. influenzae LOS induced
increases in cultured human middle ear epithelial (HMEE) cell
expression of IL-1β , TNF-α , MIP-1β , IL-8, IL-6, and MCP-1
mRNA expression (196). Barrett et al. (197) demonstrated that
LPS activated ICAM-1 receptors, IL-8, and NF-κ B, a ubiquitous
transcription factor complexed to its inhibitor within the cyto-
plasm in in vitro studies using rabbit middle ear epithelial cells.
Endotoxin is reported to be present in a high percentage of
middle ear effusions and even in nonpurulent MEEs (198-200).
In an experiment examining the endotoxin levels in mucoid,
serous, adult, and acute MEEs, endotoxin was found in 76.8%
of the mucoid effusions, 55.6% of the serous effusions, 47.8% of
effusions from adult patients, and 100% of acute effusions (201). 
H. influenzae type b endotoxin and the outer cell wall of non-
typable H. influenzae induced OM in guinea pigs (202, 203).
Killed S. pneumoniae produced an inflammatory reaction con-
sisting of epithelial metaplasia, increasing edema, and a PMN
infiltrate in MEEs in a chinchilla model (204). H. influenzae and
S. pneumoniae antigen was present in 26% and 21% of human
effusion samples, respectively (205). Inoculating a higher con-
centration of LPS into the middle ear caused the development
of a longer-term OME in the guinea pig (206). In a mouse model
it was shown that the subepithelial space of middle ear mucosa
was severely thickened with the infiltration of a large number of
mononuclear cells induced by endotoxin (207). Bacterial endo-
toxin delayed mucociliary transport in the chinchilla ME, suggest-
ing that bacterial components trapped in ME may sustain the in-
flammation and contribute to the chronicity of the MEE (208).
MEE itself induces inflammatory reactions in the ME cavity in
animals (120). Intratympanic inoculation of human MEEs induced
OME in guinea pigs and reduced ciliary activity (209). Maeda et
al. (207) found that endotoxin-induced OM resulted in mucoid
MEEs and that eustachian tube dysfunction is essential to a serous
MEE. Addition of endotoxin in vivo caused an increase in mucos-
al cell proliferation and the formation of epithelial effusion prod-
ucts (210, 211).
In view of the high incidence of endotoxin in MEE, a number
of studies have focused on the cochlear effects of endotoxin to
determine whether endotoxin can induce pathological changes,
including hearing loss, after direct injection of the inner ear or
subsequent to the injection of the ME with endotoxin from var-
ious sources (190, 212-214). When 1 mg/mL of endotoxin was
applied onto the round window membrane in normal guinea
pigs, elevation of auditory brain stem response (ABR) thresh-
olds were reported (213). Demaria (215) showed that endotox-
in shed by NTHi during experimental OM penetrates the inner
ear and binds to both tissue components and inflammatory cells
in both the middle and inner ear. Therefore, it is probable that
endotoxin is a significant factor that can induce sensorineural hear-
ing loss as a sequela of OM. 
Transcription factor, toll-like receptor and cytokines
Among a variety of transcription regulators, NF-κ B has been shown
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bers of genes including cytokines, chemokines, and other medi-
ators involved in inflammatory responses (216). NF-κ B is a dimer-
ic transcription factor that is composed of p50 (NF-κ B1) and p65
(RelA) subunits (216). NF-κ B is rapidly activated by a large spec-
trum of chemically diverse agents and cellular stress conditions
including bacterial LPS, microbial and viral pathogens, cytokines
and growth factors (197, 217, 218). In resting cells, NF-κ B is re-
tained in the cytoplasm but enters the nucleus in response to vari-
ous stimuli including bacterial infections. Activation of NF-κ Bi s
controlled by an inhibitory subunit, Iκ B, which retains NF-κ Bi n
the cytoplasm. The activation of NF-κ B by a NF-κ B translocation-
dependent pathway requires sequential phosphorylation, ubiq-
uitination, and degradation of Iκ B as well as consequent exposure
of a nuclear localization signal on the NF-κ B molecule. Multiple
kinases have been shown to phosphorylate Iκ B at specific amino-
terminal serine residues (219, 220). Phosphorylation of Iκ Bb y
Iκ B kinase (IKK) pathways leads to the nuclear translocation of
NF-κ B which, in turn, activates expression of target genes in the
nucleus. NTHi, a well-known pathogen of otitis media, strongly
activates NF-κ B in a cultured human middle ear epithlelial cell
line (HMEEC-1) via NF-κ B translocation-dependent and indepen-
dent pathways. The NF-κ B translocation-independent pathway
involves activation of the MKK3/6-p38 mitogen-activated pro-
tein kinase (MAPK) pathway (221). It has also been shown that
NF-κ B is synergistically induced by the combination of TNF-α
and NTHi (222).
In the host innate immune system, the surface epithelial cells
recognize the invading bacteria by directly interacting with pa-
thogen-associated molecular patterns on a variety of bacteria via
Toll-like receptors (TLRs) expressed on the host (223). Of these,
TLR2 has been well studied by researchers. TLR2 can respond
to a variety of Gram-positive products, including peptidoglycan,
lipoprotein, lipoteichoic acid, and lipoarabinomannan (224). TLR2
also plays an important role in the NTHi-induced NF-κ B activa-
tion (221). Collectively, when NTHi binds TLR2, several key in-
flammatory mediators including IL-1β , IL-8, and TNF-α are up-
regulated by the activation of NF-κ B (221).
On the other hand, the promoter regions of many of the
TNF-α -regulated genes contain DNA binding sites for NF-κ B.
TNF-αalso contributes to the activation of NF-κ B. The interac-
tion of TNF-αwith its receptor has been shown to activate sev-
eral signaling pathways, including a MAPK/extracellular signal-
regulated kinase kinase 1 (MEKK-1)-dependent MAPK signal-
ing pathway and a NF-κ B-inducing kinase (NIK)-IKK-Iκ Bαpath-
way (225). Watanabe et al. (222) showed that NTHi and TNF-α ,
when present together, synergistically induce NF-κ B activation via
two distinct pathways: a NF-κ B translocation-dependent and an
independent pathway in epithelial cell lines including HMEEC-1.
Mucous secretion and mucoid otitis media (MOM)
MOM is characterized by viscous fluid, high in mucin concentra-
tion, which accumulates in the ME cavity. Hypersecretion of
mucous glycoprotein can be harmful to the mucociliary transport
system (227). Mucocilary dysfunction in the tubotympanum plays
an important role in the pathophysiology of OME and the rheo-
logical properties of MEE also play an important role in the process
of recovery from OME (228, 229). Mucin, or mucus glycoprotein,
is the major viscous component of MEE (230). There was a pos-
itive correlation between the viscoelasticity of MEE and goblet
cell densities of middle ear mucosa (231). Mucociliary clearance
is dependent on the rheological properties or viscoelasticity of
MEE (232, 233). Mucociliary transport rates reduce when the
viscosity of effusion is excessively high or low (233). Mucociliary
dysfunction was suggested in the middle ears of children with
OME caused by a decrease in the number of ciliated cells, hyper-
plasia of goblet cells, and an abnormal interaction of cilia and mucus
that would fail to transport mucus, possibly causing mucus accu-
mulation in the ME cavity (234).
Proinflammatory cytokines, such as TNF-α and IL-8, may play
an important role in the pathogenesis of MOM. Mucoid effusions
from human MEE samples contained higher levels of IL-8 than
serous effusions (235, 236). TNF-αenhances PLA2 expression
(237). PLA2, exogenously administrated, increased mucous gly-
coprotein secretion in cultured chinchilla middle ear epithelial
cells (238). This suggests that PLA2 increases the release of arachi-
donic acid, since arachidonic acid metabolites are known to be
involved in mucous glycoprotein production and secretion (159,
239, 240). TNF-αmarkedly increased the steady-state level of
MUC2 mucin mRNA in ME epithelial cells of rats in a dose- and
time-dependent manner (237). Inoculation of TNF-α into the ME
cavity followed by ET obstruction stimulated mucous cell meta-
plasia hyperplasia in the ME cleft, accompanied by abundant mucin
or mucin-like glycoprotein in the MEE (241). Concentrations of
nitric oxide metabolites were higher in MOM than in serous OM
(242). TNF-αwas reported to stimulate secretion of mucin by
guinea pig tracheal epithelial cells via mechanisms involving acti-
vation of NO synthase (NOS) and generation of NO (243). The-
refore, it is conceivable that NO may also play an important role
in the pathogenesis of MOM.
PAF also stimulates secretion of mucus glycoprotein mediat-
ed by arachidonic acid metabolites, especially metabolites of the
lipoxygenase pathway via a PAF-receptor dependent mechanism
(244), and inhibits mucociliary clearance of the eustachian tube
(245). The expression of soluble adhesion molecules, such as inter-
cellular adhesion molecule-1 (ICAM-1), is known to be upregu-
lated at the cell surface in inflammatory disease. The levels of
soluble ICAM-1 in mucoid effusions were reported to be signif-
icantly higher than those in serous effusions (246). More recent-
ly, Maeda et al. (207) demonstrated that additional administra-
tion of endotoxin was needed to produce mucoid MEE after the
induction of serous MEE by ET blockage. Collectively, mucoid
otitis media appears to be a more inflammatory and chronic form
of OM than serous OM.
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the TLR2-MyD88-TAK1-NIK-IKKβ /γ -Iκ Bα pathway to mediate
NF-κ B-dependent MUC2 mucin transcription in the epithelial
cell lines including in the human middle ear epithelial cell line
HMEEC-1 (247). Jono et al. (248) also showed that NTHi strong-
ly induced up-regulation of MUC5AC mucin via activation of
the Toll-like receptor 2-MyD88-dependent p38 pathway in the
epithelial cell lines including HMEEC-1. Activation of TGF-β -Smad
signaling, however, led to down- regulation of p38 by including
MAPK phosphatase-1 (MKP-1), thereby acting as a negative reg-
ulator for MUC5AC induction (248).
The role of cytokines in cholesteatoma pathogenesis
Cholesteatomas are characterized by migration of keratinized
squamous epithelium positioned in a fibrous stroma into the mid-
dle ear and mastoid cavity. This review has focused mainly on
the associated inflammatory process seen in chronic otitis media
and acquired cholesteatoma. Although the pathophysiology re-
mains to be clearly elucidated, it is presumed to be multifactori-
al, as many theories have been proposed and investigated (249).
Generally, it is thought that cholesteatomas form from a retrac-
tion pocket in the pars flaccida of the tympanic membrane (TM).
Predisposing conditions causing TM invagination appear to be
chronic eustachian tube dysfunction with negative middle ear
pressure, repeated bacterial infections, or chronic otitis media.
In many of these cases, this induction of cholesteatoma forma-
tion seems to be related to both internal molecular dysregulation
and external stimuli in the form of pro-inflammatory cytokines,
growth factors and/or bacterial toxins. Acquired cholesteatomas
almost universally arise in the setting of inflammation and infec-
tion. Inflammatory granulation tissue always appears with invad-
ing epithelium in active human cholesteatomas (250) and exper-
imental animal cholesteatomas (251). The inflammatory milieu
that occurs in the setting of chronic otitis and cholesteatoma has
been well delineated. As previously described, a large number
of pro-inflammatory cytokines, prostaglandins, growth factors,
and inflammatory cells have been identified in both chronic oti-
tis media and cholesteatoma (249, 252-255). 
The pathobiologic reason for the observed increase in prolif-
eration in cholesteatoma tissue is not completely understood.
Recent studies indicate a transcription factor, termed inhibitor of
differentiation (Id1), is involved in the proliferation of choles-
teatoma epithelium via an NF-κ B/cyclin D1 dependent mecha-
nism (6, 187). First, Id1 is upregulated in the rat middle ear
mucosa following the infection with penumococcus (39). Second,
upregulation of Id1 results in thickening of the middle ear mucosa
with epithelial cell metaplasia. This is via the upregulation of cell
cycle activity: the NF-κ B/cyclin D1/cyclin-dependent kinases
(Cdk2/4)/E2F/proliferating cell nuclear antigen (PCNA) signal-
ing (Fig. 2). Phospholipase C-γ 1 is the central molecule that acti-
vates the phospho-inositide second messenger signal transduction
pathway. It is responsible for transducing the signals from the
tyrosine kinase and epidermal growth factor receptors (EGFR).
Increases in signal transduction from EGFRs result in a variety
of cellular events including the induction of hyperplasia, growth,
proliferative cytokeratin expression, and tumor invasiveness.
Immunohistochemical and protein immunoblot studies showed
that phospholipase C-γ 1 is over-expressed across the matrix of
cholesteatoma (256). In cholesteatoma, EGFR expression is not
limited to the basal layer, as it is in normal squamous epithelia.
Its expression is increased in the suprabasal strata (257, 258).
75% of cholesteatoma keratinocytes express EGFR as opposed
to only 10% of normal and canal keratinocytes (259). Transforming
growth factor-α , the ligand for EGFR is also expressed across all
layers of the cholesteatoma matrix (258).
Although the molecular characteristics that contribute to ch-
olesteatoma growth dysregulation have been qualitatively des-
cribed, the exact pathobiologic mechanism leading to the observed
hyper-proliferative state remains hypothetical. Evidence seems
to point to the inability of cholesteatoma cells to abrogate pro-
liferative and migratory signals from local inflammatory cells.
Cytokines secreted by these local immune cells may create alter-
ations in internal keratinocyte biochemical pathways that lead to
the above-described hyper-proliferative phenotype. Moreover,
noxious stimuli in the form of bacterial products and toxins could
magnify this response. Ottaviani et al. (260) showed that the peri-
matrix of cholesteatoma showed a sharp reactivity to the ICAM-
1 and to the endothelial leukocyte adhesion molecule (ELAM-
1), both responsible for the homing of inflammatory cells at the
epithelial-stromal junction of cholesteatoma. This over-expression
of ICAM-1 and ELAM-1 seems to show that keratinocytes in
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Fig. 2. Schematic representation of the Id1-induced cellular hyperpro-
liferation and abundant keratin 10 production pathways in keratinocytes.
CD1: cyclin D1; Cdks: cyclin-dependent kinases (cdks 4/6); Rb: reti-
noblastoma; Rb-P: phosphorylated Rb; E2F: a transcription factor that
drives the Go/G1-to-S phase transition of cells.cholesteatoma are in an activated state and that their hyperpro-
liferation is mediated through inflammatory and/or autocrine
cytokines. To this point, Huang et al. (261) has shown that GM-
CSF, a protein that is highly expressed by monocytes and
fibroblasts within the subepithelial stroma of cholesteatoma, is
present at high levels throughout all layers of cholesteatoma.
GM-CSF is known to induce in vitro keratinocyte proliferation
and protein production.
It is theorized that intense infiltration of cholesteatoma by
immune cells leads to chronic inflammation via continuous over-
production of certain cytokines. The reasons for failure to con-
trol this inflammatory response are not completely understood.
It is possible that the microenvironment of the cholesteatoma
state, namely granulation tissue, bacterial pathogens, and inva-
sive hyper-proliferating keratinocytes, leads to a perpetual inflam-
matory milieu. Studies have shown the overall number of mast
cells to be highly increased in acquired cholesteatoma (262). Mast
cells are responsible for the secretion of a variety of potent cyto-
kines many of which have been implicated in the pathogenesis
of cholesteatoma. These include IL-1, IL-6, GM-CSF, interferon-
gamma (IFN-γ ) and TNF-α . Much like increased mast cell infil-
tration, acquired cholesteatomas contain increases in the num-
ber activated T-cells and macrophages (263). 
Among the above-mentioned cytokines, TNF-α plays a major
role in acquired cholesteatoma biology (264, 265). It appears to
be preferentially localized to the connective tissue and epitheli-
um of human cholesteatoma samples when compared to normal
ear canal skin. In vitro, it has been shown to induce the prolifer-
ation, protein synthesis and terminal differentiation of basal ker-
atinocytes. Although mainly secreted by activated macrophages,
mast cells and cholesteatoma keratinocytes may also produce it.
It induces osteoclast-mediated bone resorption (266), stimulates
fibroblasts to secrete collagenase and prostaglandin E2 that in turn
cause local soft tissue destruction (267), and may cause the resorp-
tion and inhibition of proteoglycans in cartilage (266-268). Fur-
thermore, the levels of TNF-α in acquired cholesteatoma were cor-
related to the amount of inflammatory cell infiltration, bony de-
struction, and severity of infection (269). These facts all suggest
that TNF-α plays a pivotal role in cholesteatoma pathogenesis.
Similarly, IL-1 was identified in the epidermis of cholesteatoma
(270). IL-1 is produced both by cholesteatoma epithelial cells and
by the inflammatory cells of the granulation tissue environment
(252). Levels of both IL-1α and IL-1β appear to be much more
elevated in cholesteatoma than in normal squamous epithelium
(271). IL-1 has been implicated in the bony resorption process
(272), and has been shown to stimulate the proliferation of ker-
atinocytes (273). 
Matrix metalloproteinases (MMPs) have been implicated as cru-
cial agents in the development of bony erosion seen with choles-
teatoma. MMPs are important in the physiologic turnover of the
cholesteatoma epithelium extracellular matrix. Normally, their
activity is tightly controlled, as an increase in their activation would
cause denudement of the extracellular matrix and increased inva-
siveness by the epithelium. In cholesteatoma, studies have indi-
cated a clear imbalance in the regulation of MMPs, with an overall
upregulation of MMP expression and a decrease in MMP inhibitors
resulting in degradation of the extracellular matrix. This causes
the aggressiveness seen in cholesteatoma with regards to its inva-
siveness and bony destruction (274, 275). According to Wilmoth
et al. (276), MMP2 levels were increased with exposure to LPS or
TNF-αin cultured gerbil TMs. This supports a link between
inflammatory mediators and the secretion of potentially destruc-
tive MMPs in the TM, which may contribute to the pathogenesis
of cholesteatoma.
Interaction between middle and inner ear
Most of the middle ear inflammatory mediators and toxins from
the middle ear enter into the inner ear through the round window
membrane (277). It has been reported that the passage through
the round window membrane (RWM) for small molecules is by
passive diffusion and for large molecules by endocytosis (278).
The blood-labyrinth barrier (BLB) also plays a primary role in the
homeostasis of ion concentrations in the endolymph and periymph.
Like other barrier systems, tight juctions within the capillaries of
the spiral ligament form the morphological site of the BLB and
prevent the passage of substances from blood into the fluid in the
inner ear. Unlike other barrier systems, however, the BLB seems
to be less permeable to several ions (sodium, chloride and calci-
um) and differentially modulates the passage of larger substances
in proportion to molecular weight (Fig. 3) (279).
Ion channels, including the delayed rectifier K
+ channel, Ca
2+-
dependent K
+ channel, Ca
2+ voltage-sensitive channel, and recep-
tors such as N-metyl-D-aspartic acid (NMDA) and nicotinic acetyl-
choline receptors (nAchRs) have been localized to the stria vas-
cularis, inner hair cells, and outer hair cells and are the primary
factors responsible for maintaining the electrical potential of the
hair cells and the process of auditory transduction (280). More
than 75 different ion channels have been identified. Proper reg-
ulation of ion channel conductance is mediated by protein phos-
phorylation. Ion channel disorders such as tinnitus or metabolic
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Fig. 3. Pathological effects of inflammatory mediators in otitis media.
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Inner ear damagedisorders are characterized by a leakage in the apical or lateral
potassium channel, affecting intracellular calcium levels. 
CONCLUSIONS
Inflammatory mediators play a central role in the pathogenesis of
OM and cholesteatoma by initiating and maintaining the inflam-
matory response to infection and injury. Inflammatory mediators
may be one of the reasons that some patients progress from acute
to COM and cholesteatoma. It is possible that inflammatory medi-
ators such as histamine and PAF can lead to eustachian tube dys-
function resulting in decreased mucociliary clearance. This could
lead to retained bacterial products such as lipopolysaccharide, cell
walls, and bacterial antigens in the middle ear cleft causing a chron-
ic inflammatory reaction with continual release of cytokines and
arachidonic acid metabolites resulting in further inflammation
and host cell damage. Another possible mechanism is through
inflammatory mediators such as TNF-α , interleukin-l, and PAF
induction of mucin secretion in the middle ear epithelium. This
would cause increased viscosity of the middle ear effusion and
may lead to decreased mucociliary clearance and retention of
bacterial products causing chronic inflammatory reactions and
mediator release.
Future studies are necessary to elucidate the roles of the newly
discovered chemokines in the pathogenesis of OM and cholestea-
toma. More studies are needed on the use of specific blocking
agents to inflammatory mediators with the aim of discovering
new treatment options for chronic otitis media and cholesteatoma.
The future holds much promise in the field of inflammatory medi-
ator research and through new discoveries the pain and suffer-
ing associated with otitis media can be reduced.
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